Nanomaterials are particles or fibers with at least one of the three dimensions in the size range between 1 and 100 nm. Owing to unique physical and chemical properties, nano-sized particles (NPs) have a variety of industrial uses and are more and more prevalent in everyday life. However, despite the growing number of nanotechnology products, health risk assessment of NPs is in its early infancy. The potential adverse effects of NPs on prenatal development are even less well investigated. This article summarizes the literature on the developmental toxicity of NPs. Generally, the studies are very recent and include ex vivo experiments using non-mammalian species, in vitro assays (mouse embryonic stem cell test) and in vivo investigations using rodents. Very little has been published on the effects of NPs on the development and function of the human placenta or on the transference of NPs into the human embryo and fetus. Some limitations of using ex vivo and in vitro assays to predict adverse effects of NPs on human prenatal development are discussed in this overview. The structural and functional differences between the rodent and human placenta in early pregnancy and their possible relevance to the transplacental passage of NPs are also commented upon.
Introduction
Nano (n)-from the greek "nannos" ("dwarf")-refers to
10
-9 of a particular unit (e.g., 1 meter = 10 9 nanometers; 1 liter = 10 9 nanoliters; 1 gram = 10 9 nanograms). It is one of 20
Latin or Greek prefixes that denote decimal multiples (10 n ) or submultiples (10 -n ) of units in the International System of Units (SI). Over past decades, the prefix nano has also been used to define new fields of human endeavor such as the nanosciences (i.e., the study of the properties of ultra-small structures, materials and devices usually with dimensions ranging from 0.1 to 100 nm) and nanotechnology (i.e., the design, characterization, production and application of structures, devices and systems by controlling shape and size on a nanometer scale).
The emergence of nanotechnology seems to have been in- are on the nanometric range scale" 6, 7 .
Feynman, in his seminal lecture, pointed out that, when the dimensions of a material are extremely reduced, approaching the atomic or molecular level (nanometer scale), some of its physical properties may dramatically change. As dimensions of a material are reduced, physical properties initially remain unaltered, then small changes occur and when size drops below a certain level (e.g., <100 nm) i drastic changes may occur.
Some size-related changes, such as the increased surface area to volume ratio (or surface area per unit of mass), are gradual modifications that become more and more important as particle size decreases. Other changes in physical and chemical properties, however, occur at critical points when particle size reduction approaches the nanoscale. These "quantum effects" may involve changes in basic properties such as melting point and color, alterations in aerodynamic behavior and increases in the percentage of atoms and molecules in the material that are on the surface of the particle. All these changes of physical and chemical features may affect interactions of particles with biological systems and thus it seems fair to assume that the health effects and toxicity of materials can also be drastically affected by nanoscaling.
As far as safety regulation is concerned, nanotechnology products are usually defined by their size and not by chemical composition. There has been, however, some controversy over i The definition recommended by the European Commission states that "Nanomaterial means a natural, incidental or manufactured material containing particles, in an unbound state or as an aggregate or as an agglomerate and where, for 50% or more of the particles in the number size distribution, one or more external dimensions is in the size range 1nm-100 nm". (2011/696/EU; Official Journal L, 275(2011) pp. [38] [39] [40] . Although some consensus has been reached on the size range of nanomaterials (1-100 nm) (ISO 2012; http://www.iso.org/obp/ui/#home), in fact there is no clear size threshold or point for changes in physicochemical properties, thus the chosen 100nm cut off was an arbitrary and political choice rather than a science-based decision.
ii Occupational exposure to manufactured or engineered nanomaterials was originally regulated as "particulates not otherwise regulated" (PNOR) by US OSHA (2006) 9 .
the definitions of the terms nanoparticle and nanoparticulate and how many dimensions must be less than 100 nm to meet such definitions 8,ii . If at least one dimension (of a three-dimensional structure) is on the scale of 1 to 100 nm, it is referred to as a "quantum well', while if two sides are on the nanometer scale, it is called a "quantum wire". If all three dimensions of the manufactured structure are of nanometer lengths it is referred to as a "quantum dot".
Nanomedicine and nanotoxicology
Nanomedicine is a novel term designating a promising field that has emerged from the successful marriage of nanotechnology and medicine 10, 11 . The potential application and incorporation of nanotechnology into clinical practice mainly involves the development of new pharmaceutical products for treatment (e.g., nanoparticulate drug-delivery systems, nanoengineered prosthetics for implants), diagnosis, therapy and monitoring of morbid conditions (e.g., biomarkers, biosensors and contrasts for diagnostic imaging procedures) 12, 13, 14 .
one advantage of making use of nanotechnology in drug development is the possibility of overcoming the low aqueous solubility and poor bioavailability of some active ingredients 15 . The reduction of particle size leads to an increase in the dissolution rate of solid formulations (pills, tablets) and further nanosizing also enhances the rate and extent of active ingredient absorption (i.e., its oral bioavailability) to levels not attainable with typical micronized drug products 16 . In principle it is also possible to develop nanoparticulate systems that deliver active pharmaceutical ingredients at a target tissue or cell (e.g., tumors).
iii Nanotechnology-based drug delivery systems are a particularly promising therapeu- 
Nanotoxicology or hazard assessment of nanoparticles
The prefix "nano" was first added to toxicology early this century to define a new subcategory of this scientific disci- iii A drug delivered directly at a therapeutic target is reminiscent of Paul Ehrlich's concept of a "Magic Bullet" ("magische Kugel") or the ideal therapeutic agent that would selectively hit the pathogen causing no undesirable effects or injury to patient's organs and tissues. iv in rios-Doria et al's study 17 , particle sizes of encapsulated anticancer drugs were 30-80 nm. v The general mechanism underlying the tumoritropic properties of some anticancer proteins was originally reported by Matsumara and Maeda 18 who also introduced the idea of EPR in 1986. Further studies described that the endothelial layer of tumor blood vessels is poorly structured and has larger intercellular gaps (0.5-2.5 mm wide) 20, 21, 22 . vi Anti-tumor activity was tested in vivo in murine 4T1 breast cancer and ovarian cancer models 19 . vii the "t 4 -transatlantic think tank for toxicology" workshop 36 , held in 2010, at the 10 th anniversary of the US NNI, discussed strategies to assess the safety of nanotechnology products. The t 4 wokshop was organized by the Jonhs Hopkins Center for Alternatives to Animal Testing (CAAT), a center committed to the Three Rs (replacement, reduction and refinement of animal use).
Developmental toxicology of nanostructured materials
In 2011, the report of an international workshop vii on the assessment of safety of nanotechnology products remarked that, "we are neither at the beginning of understanding the potential health effects, nor are we at the end, having all the answers the public, regulators, and policy makers require" 36 .
According to workshop attendees' opinion, nanotoxicology was perhaps at "the end of the beginning" of creating a roadmap for a predictive testing strategy 36. As far as reproductive and developmental hazards are concerned (i.e., developmental nanotoxicology), however, we are still taking the very first steps towards this goal.
In fact, a search in the Pubmed data base (01 September 2013) revealed that developmental nanotoxicology has not only emerged much later than the mother field of nanotechnology, but it has also elicited less research interest than the study of toxicity of nanomaterials to mature individuals (Table 1) 37 .
Ema et al. (Table 1) consistently showed that there are relatively few studies on the reproductive and developmental toxicity of nanoparticles and that "next to nothing" is known about the effects of NPs on the placenta during early human pregnancy.
As shown in Table 2 50 and freshwater snails 48 ), and sea urchin 44, 47 embryos. As shown in Table 2 , exposure of non-mammalian embryos to a diversity of NPs gives rise to hatching delays, abnormal morphogenesis, increased embryo mortality and other adverse developmental outcomes. In some cases (e.g., fullerene C60), evidence has been presented that the oxidative stress elicited by the NP is the underlying mech- If not secondary to placental dysfunction and/or disturbances in maternal homeostasis (i.e., maternal toxicity), adverse effects of NPs on prenatal development arise from the transference of NPs via the placenta into the embryonic/fetal compartment ( Figure 1 ).
In non-mammalian test systems, eggs (and the embryos within the eggs) are directly exposed and thus these assays NPs and liposomes in the maternal blood may fuse with ST membrane and enter the cytoplasm where they can be disassembled thereby releasing their contents directly into ST cytosol. NP contents then diffuse to the villous stroma and the fetal capillary entering its lumen. An additional possibility (not depicted in the Figure) is the NP or liposome to remain intact within the cytoplasm and be fused with the ST basal membrane (BM) thereby releasing its contents into the villous stroma. B -Endocytosis. NP might be taken by endocytosis and either be degraded (in endosomes) thereby releasing their contents in the ST cytosol, or be transported via transcytosis to the villous stroma. Moving by simple diffusion the NPs (via pores between endothelial cells), or their contents (via both pores and endothelial cell cytoplasm) may then reach the lumen of the fetal capillary. C-Receptormediated mechanism. Ligand-modified NPs might bind to ST apical membrane receptor undertaking endocytosis. They may either be disassembled releasing their contents into the ST cytosol or be transferred by transcytosis into villous stroma. D-NP with certain features in terms of dimensions, charge, or surface composition may fail to penetrate the apical membrane of the ST thereby being unable to cross from the maternal to the fetal compartment. In any of cases of NPs that penetrate the apical membrane of ST (A,B,C) an additional possibility is the retention of the intact NPs within the ST cytoplasm.
developmental toxicants that would not reach the mammalian embryo owing to the protective roles of the placenta and the maternal organism but, cannot detect harmful effects on the embryo arising from maternal toxicity and placental dysfunction. In other words, test systems (in non-mammals or in vitro)
in which embryo exposure to NPs do not occur through the placenta are prone to yielding both false positive and false negative results with respect to potential hazards to developing mammalian/human conceptuses.
transplacental transfer and toxicity to mammalian embryos
Kinetic studies of classical xenobiotic compounds suggest that highly hydrophilic and large molecules (>1 kDa) are unlikely to be transferred across the placenta to the conceptus xii . Nonetheless, as highlighted by Maynard et al. 29 , due to abrupt size-dependent changes in interactions with biological systems, the toxicity of engineered NPs (an "emergent risk") may arise from the unanticipated penetration of particles and fibers into tissues normally inaccessible to large molecules and particles 29 .
As shown by studies depicted in Table 3 , maternal exposure to a variety of manufactured NPs was associated with harmful effects on mouse and rat embryos 61,70,72,73,74,75,76,77,78,79,80 ,81,82,83,84 . In at least three studies 73, 77, 82 ,xiii , NPs were detected in the prenatally exposed offspring thereby indicating that tested
NPs were transferred to the developing conceptus across the placenta. Blum et al. 81 , however, detected NPs (CdO) in the placenta and maternal organs of treated mice but not in their fetuses. Therefore, the embryotoxic effects of CdO NPs noted by the authors (e.g., delayed fetal and neonatal growth) were probably secondary to effects on the placenta and/or maternal toxicity (Table 3) .
Overall, the rodent studies performed to date indicate that the exposure of pregnant females to different types of NPs may result in a variety of adverse outcomes of pregnancy such as embryo mortality, intra-uterine growth retardation, structural anomalies, and altered gene expression in the prenatally exposed offspring (Table 3) . Some studies have provided additional kinetic data suggesting that developmentally toxic NPs crossed the placenta so that embryos were directly exposed. In at least one case, however, embryotoxic effects of NPs seemed to have been secondary to maternal and/or placental toxicity 81 . The absence of discernible adverse effects on embryo development even when NP exposure resulted in marked maternal toxicity has also been reported 79 . In a study by Chan & Shiao 83 mouse blastocysts were exposed to NPs (CdSe QDs) in vitro, and then implanted into dams' uteri.
In this case, the authors found detrimental effects of tested NPs on embryo development both in vitro (e.g., blastocyst
cell apoptosis) and in vivo after transfer and implantation of in vitro-exposed embryos.
Owing to interspecies differences with respect to placental structure and function, toxic effects of NPs on development noted in rodents may not occur in humans 85 (Tables 4,5, Figure 2 ). In the rat, the inverted visceral yolk sac (intimately apposed to the uterine tissues) is the major structure mediating maternal and embryonic exchanges in early pregnancy (GD 7.5-12) 85, 86 . In humans, however, there has been no indication that histiotrophic nutrition (via a yolk sac) is an important pathway for nutrient acquisition vis a vis chorionic villi mediated hemotrophic exchanges 86 . It has been demonstrated that substances that inhibit rodent yolk sac function such as trypan blue and concanavalin A are also teratogenic 87,88. the previously mentioned interspecies differences in placental structure and function, suggest that inhibitors of yolk sac mediated maternal-embryonic exchanges in rodents are unlikely to cause similar teratogenic effects in humans.
Although an explanation for some of the embryotoxic effects in Table 3 , whether or not NPs affect rodent yolk sac mediated maternal-embryonic exchanges and the extent to which they do so remain largely unclear.
Currently little is known about the transplacental transport of engineered NPs and whether NPs interfere with placental function in humans 64, 65 . Only a few studies have addressed these crucial questions. Myllynen et al. 67 observed that PE- by Sønnegaard-Poulsen et al. 66 using an in vitro (BeWo b30 choriocarcinoma cell line, MTT cytotoxicity assay) and an ex vivo (perfused human placenta) model found that silica NPs decreased BeWo cell viability at concentrations higher than 100 µg/mL. The authors also noted that the percentage of silixi In the FETAX assay 69 after frog egg laying, the jelly coat (a thick, sticky coating surrounding the egg) is removed by gently swirling the egg mass with a solution of L-cysteine. This de-jellying of embryos is undertaken to facilitate xenobiotic penetration of the egg thereby enhancing assay sensitivity to developmental toxicants. xii Exceptions to this rule are large macromolecules specifically transported by the synctiotrophoblast, for example IgG (from the 13 th week of human pregnancy onwards). xiii In Jo et al's study, pups underwent euthanasia on PND4 and so transference of NPs to pups via the maternal milk cannot be ruled out in this case. xiv PEGylation is a covalent attachment of polyethylene glycol (PEG) polymer chains to NP or another molecule. The covalent attachment of PEG to a drug or therapeutic protein can "mask" the NP or macromolecule from the host's immune system, increase its water solubility and hydrodynamic size (size in solution), and reduce its renal clearance, thereby prolonging its circulatory time. Implantation types: 1) superficial: chorionic sac is in contact with uterus lumen; 2) eccentric: chorionic sac is in a "pocket" partially separated from uterus lumen; 3) interstitial: chorionic sac is within the uterine wall losing contact with uterus lumen. Chorioallantoic placenta: formed by the chorion (outermost avascular membrane of embryonic vesicle) that is augmented by and receives vascularization from the allantois. Inverted yolk sac placenta: formed by membranes of rodent large yolk sacs, it is at times called "inverted" because outer yolk sac membranes become discontinuous at the apposition to the uterine wall, leaving the inner yolk sac membrane nearly in contact with the uterine lumen and epithelium. Rodents do not develop the definitive chorioallantoic placenta until a circulatory system is operative (i.e., in rats GD 11-11.5) whereas yolk sac placentas are not formed in primates. Exchanges between maternal and embryo/fetus circulation by a direct hemotrophic process
Exchanges of nutrients through hemotrophic process of chorioallantoic placenta are faster and more efficient than those mediated by histiotrophic process of inverted yolk placenta.
Figure 2.
Differences between rodents (eccentric) and humans (interstitial) regarding the mode by which placentation takes place in early pregnancy. Note that in the eccentric type of placentation, the chorionic sac is within a "pocket" that is partially in contact with the uterine lumen, whereas in the interstitial type, the chorionic sac is entirely enveloped by the uterus wall keeping no contact with its lumen.
xv Kaitu'u-Lino et al 89 used bacterially derived nanospheres (400nm in diameter) known as "EnGeneIC Delivery Vehicles" (EDVs) to target the epidermal growth factor receptor (EGFR) and so promote trophoblast tissue specific delivery of the antineoplastic drug doxorubicin. Placental targeting was achieved with the presence of bispecific antibodies against EGFR on the sphere surface. Since EGFRs are highly expressed on the placenta surface, doxorubicin (an antiproliferative agent) was specifically delivered to the target abnormal tissue. It is of note that these EDV are larger than 100 nm in diameter, and so technically they do not fit the previous (arbitrary) definition of NP. Differences between rodents and humans with respect to the structure and function of the placenta, particularly in early pregnancy, may eventually lead to false positive findings at this confirmatory testing step. Hence, more studies on the passage through and effects of NPs on human placental development and functioning are needed.
In this review the authors' focus was mainly on the evaluation of potential health hazards to development posed by engineered NPs, i.e., the first step (hazard identification) of risk assessment. Nonetheless it is worth mentioning that good quality data is also missing on quantitative estimations of human exposure (including women of childbearing age) to existent NPs and without this information it is impossible properly to assess and manage their health risks.
The identification of potential hazards and the assessment of human health risks posed by the myriad of novel nanotechnology products is one of the challenges currently faced by toxicologists, particularly by those who deal with reproductive and developmental toxicology. Actually, any safe use of this fascinating novel technology in medicine and consumer products requires an equally innovative toxicological testing approach.
